Related Experiment Video
Updated: May 20, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Apheresis in the treatment of idiopathic dilated cardiomyopathy
1Department of Laboratory Medicine and Pathology, Division of Transfusion Medicine, Mayo Clinic, Rochester, Minnesota, USA. winters.jeffrey@mayo.edu
Insights
Dilated cardiomyopathy (DCM) may be an autoimmune disorder. Apheresis, a blood filtering technique, shows promise in treating idiopathic DCM, but more research is needed to confirm its effectiveness.
Area of Science:
- Cardiology
- Immunology
- Nephrology
Background:
- Dilated cardiomyopathy (DCM) is a leading cause of heart failure and cardiac transplantation in the US.
- Idiopathic DCM, lacking a clear cause, is increasingly suspected to have an autoimmune basis, potentially triggered by viral myocarditis.
Purpose of the Study:
- To review the hypothesized autoimmune mechanisms in idiopathic DCM.
- To examine the published evidence for apheresis techniques in treating idiopathic DCM.
Main Methods:
- Literature review of studies investigating apheresis (including immunoadsorption and plasma exchange) for idiopathic DCM.
- Analysis of the proposed autoimmune pathways involved in DCM pathogenesis.
Main Results:
- Evidence suggests apheresis may be a viable treatment option for idiopathic DCM.
- The autoimmune hypothesis for idiopathic DCM is supported by a growing body of literature.
Conclusions:
- Apheresis demonstrates potential efficacy in managing idiopathic DCM.
- Further research is essential to identify predictive markers for treatment response and optimize apheresis protocols.
Abstract:
Dilated cardiomyopathy (DCM) causes significant morbidity and mortality and is the number one indication for cardiac transplantation in the United States. A large percentage of cases of DCM have no identifiable cause with evidence suggesting that these may represent an autoimmune disorder triggered by viral myocarditis. There is a growing body of literature suggesting that a number of immunoadsorption techniques, as well as plasma exchange, may have a role in the treatment of idiopathic DCM. The hypothesized autoimmune mechanism behind idiopathic DCM as well as the published evidence for the use of apheresis in this disorder are reviewed. The available evidence suggests that apheresis may be an effective treatment, but additional research is needed to identify markers that will predict response and the most effective apheresis technique.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Myocarditis III: Medical Management
Cardiomyopathy I: Introduction and Classification
